Jul 30 |
Top Midday Gainers
|
Jul 30 |
Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients
|
Jul 30 |
Imunon stock rallies 157% on Phase 2 study results for IMNN-001
|
Jul 30 |
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
|
Jul 30 |
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
|
Jul 29 |
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
|
Jun 5 |
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
|
May 16 |
IMNN: Results from OVATION 2 Study in Mid-2024…
|
May 15 |
Imunon files for $75M mixed shelf offering
|
May 15 |
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
|